Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Zevra Therapeutics (NASDAQ:ZVRA) from a buy rating to a hold rating in a research report released on Monday morning.

A number of other analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Zacks Research lowered shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Finally, HC Wainwright began coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Zevra Therapeutics Stock Up 3.1%

NASDAQ:ZVRA opened at $11.15 on Monday. The firm has a market capitalization of $625.85 million, a P/E ratio of -53.10 and a beta of 1.49. Zevra Therapeutics has a 1-year low of $6.19 and a 1-year high of $13.16. The company’s fifty day moving average price is $9.33 and its 200-day moving average price is $9.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). The business had revenue of $25.88 million during the quarter, compared to analyst estimates of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. As a group, equities research analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were acquired at an average cost of $9.16 per share, with a total value of $45,800.00. Following the completion of the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $412,200. This trade represents a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the transaction, the chief executive officer directly owned 222,016 shares in the company, valued at approximately $2,402,213.12. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC lifted its stake in shares of Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after buying an additional 8,020 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares in the last quarter. Finally, Creative Planning purchased a new position in shares of Zevra Therapeutics in the second quarter worth about $92,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.